We conducted screens in K-562, a BCR-ABL chronic myeloid leukemia cell line and in A549, a KRAS-mutant lung cancer cell line with wildtype TP53, using standard CRISPR screening protocols (500x library coverage, 8–10 doublings). This evidence concerns the gene ABL1 and lung carcinoma.